11 terminated. 11 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Terminated 11 |
| Phase 1 | 2 | Terminated 2 |
Follow plerixafor: new trials by email Literature Review of plerixafor trials Research Report on plerixafor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease MGTA-145, Plerixafor - Sickle Cell Disease | Phase 2 | Terminated | Ensoma | 1 | 2022-06-24 | 2025-07-25 |
| MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies MGTA-145, Plerixafor - Related Donors Donating PBSC to a Family Member, Healthy Donors | Phase 2 | Terminated | Ensoma | 7 | 2021-06-16 | 2024-11-06 |
| Plerixafor in Diabetic Wound Healing Plerixafor, Placebo - Diabetes, Wounds | Phase 2 | Terminated | Gian Paolo Fadini | 25 | 2016-06-01 | 2019-12-19 |
| A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs CDX-301, CDX-301 and plerixafor - For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling | Phase 2 | Terminated | Celldex Therapeutics | 36 | 2014-07-01 | 2017-04-07 |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma Cyclophosphamide, Doxorubicin, Vincristine - T-cell Non-Hodgkin Lymphoma | Phase 2 | Terminated | Dana-Farber Cancer Institute | 5 | 2013-07-01 | 2023-01-30 |
| T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant clofarabine, cytarabine, busulfan - Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia | Phase 2 | Terminated | St. Jude Children's Research Hospital | 34 | 2012-08-01 | 2017-02-20 |
| Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) Plerixafor, Clofarabine - Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 22 | 2010-08-01 | 2019-08-28 |
| Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab - Severe Combined Immunodeficiency | Phase 2 | Terminated | University of California, San Francisco | 7 | 2010-08-01 | 2018-07-31 |
| O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Carmustine - Glioblastoma, Gliosarcoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 12 | 2009-02-25 | 2022-05-18 |
| AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone G-CSF plus plerixafor - Multiple Myeloma, Lymphoma, Non-Hodgkin's | Phase 2 | Terminated | Genzyme, a Sanofi Company | 5 | 2005-04-01 | 2015-05-01 |
| Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation plerixafor - Multiple Myeloma | Phase 2 | Terminated | Genzyme, a Sanofi Company | 9 | 2004-11-01 | 2014-03-13 |
Leukemia, Myeloid, Acute (4) · Lymphoma, Non-Hodgkin (3) · Myelodysplastic Syndromes (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Multiple Myeloma (2) · Anemia, Sickle Cell (1) · Chronic Limb-Threatening Ischemia (1) · Diabetes Mellitus (1) · Glioblastoma (1) · Gliosarcoma (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
Ensoma (2) · Genzyme, a Sanofi Company (2) · Celldex Therapeutics (1) · Dana-Farber Cancer Institute (1) · Fred Hutchinson Cancer Center (1) · Gian Paolo Fadini (1) · M.D. Anderson Cancer Center (1) · St. Jude Children's Research Hospital (1) · University of California, San Francisco (1)
United States (10) · Italy (1)
Brandon M. Triplett, MD (1) · Christopher C Dvorak, M.D. (1) · Gian Paolo Fadini, MD PhD (1) · Hans-Peter Kiem (1) · Jan A. Burger, MD (1) · Ji Hyun Lee, MD, MPH (1) · Philippe Armand, MD (1) · Steven Devine, MD (1)